Jedd Wolchok
Dr. Wolchok is Chief of the Immuno-Oncology Service, Human Oncology and Pathogenesis Program and the Director of the Parker Institute for Cancer Immunotherapy at MSK and holds The Lloyd J. Old Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center. Dr. Wolchok is a clinician-scientist exploring innovative immunotherapeutic strategies in laboratory models, and a principal investigator in numerous pivotal clinical trials. Dr. Wolchok has helped establish MSK as a leader in the discovery and treatment of cancers with novel immunotherapies. Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma. He supervises an NIH R01-funded basic science laboratory which is focused on investigating novel immunotherapeutic agents in pre-clinical laboratory models. The focus of his translational research laboratory is to investigate innovative means to modulate the immune response to cancer as well as to better understand the mechanistic basis for sensitivity and resistance to currently available immunotherapies. Dr. Wolchok received his BA degree from Princeton University, and his MS, PhD and MD degrees from New York University. Dr. Wolchok has received numerous honors for his work including: American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award, the Giants of Cancer Care in Melanoma Award and received the AICF Prize for Scientific excellence in Medicine. He has received the Melvin and Sylvia Griem Lectureship in Molecular and Cellular Oncology; the Alumni Achievement Award in Clinical and Translational Science from NYU, the Alfred Taubman Prize for Excellence in Translational Medical Research and Society of Surgical Oncology (SSO) James Ewing Lecturer, the RCCS Monsey Medical Devotion Award and has received the Fellow of the American Society of Clinical Oncology (FASCO) award. Most recently, he has been awarded the Mark Foundation Grant, the Distinguished Alumni Award at MSK, the AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research, 2020 HOPE funds for Cancer Research Award of Excellence, the ESMO Award for Immuno-Oncology and was awarded the Hearst foundation grant.
Abstracts this author is presenting: